;PMID: 1697481
;source_file_845.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)sentence:[e:55..176] = [t:55..176]
;2)section:[e:180..222] = [t:180..222]
;3)section:[e:226..313] = [t:226..313]
;4)sentence:[e:317..461] = [t:317..461]
;5)sentence:[e:462..599] = [t:462..599]
;6)sentence:[e:600..779] = [t:600..779]
;7)sentence:[e:781..874] = [t:781..874]
;8)sentence:[e:875..992] = [t:875..992]
;9)sentence:[e:993..1151] = [t:993..1151]
;10)sentence:[e:1152..1365] = [t:1152..1365]
;11)sentence:[e:1366..1619] = [t:1366..1619]
;12)sentence:[e:1620..1734] = [t:1620..1734]
;13)sentence:[e:1735..1801] = [t:1735..1801]
;14)section:[e:1805..1849] = [t:1805..1849]

;section 0 Span:0..49
;Biochim Biophys Acta. 1990 Aug 17;1035(2):146-53.
(SEC
  (FRAG (NNP:[0..7] Biochim) (NNP:[8..15] Biophys) (NNP:[16..20] Acta)
        (.:[20..21] .) (CD:[22..26] 1990) (NNP:[27..30] Aug)
        (CC:[31..39] 17;1035-LRB-) (CD:[39..40] 2) (-RRB-:[40..41] -RRB-)
        (CD:[41..45] :146) (::[45..46] -) (CD:[46..48] 53) (.:[48..49] .)))

;sentence 1 Span:55..176
;Cytotoxic effects of aflatoxin B1 and its association with cellular
;components  in chicken embryo primary cultured cells.
;[76..88]:substance:"aflatoxin B1"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[55..64] Cytotoxic) (NNS:[65..72] effects))
      (PP (IN:[73..75] of)
        (NP (NN:[76..85] aflatoxin) (NN:[86..88] B1))))
    (CC:[89..92] and)
    (NP
      (NP (PRP$:[93..96] its) (NN:[97..108] association))
      (PP (IN:[109..113] with)
        (NP (JJ:[114..122] cellular) (NNS:[123..133] components)))
      (PP-LOC (IN:[135..137] in)
        (NP (NN:[138..145] chicken) (NN:[146..152] embryo)
            (JJ:[153..160] primary) (JJ:[161..169] cultured)
            (NNS:[170..175] cells))))
    (.:[175..176] .)))

;section 2 Span:180..222
;Iwaki M, Kitagawa T, Akamatsu Y, Aibara K.
(SEC
  (FRAG (NNP:[180..185] Iwaki) (NNP:[186..188] M,) (NNP:[189..197] Kitagawa)
        (NNP:[198..199] T) (,:[199..200] ,) (NNP:[201..209] Akamatsu)
        (NNP:[210..211] Y) (,:[211..212] ,) (NNP:[213..219] Aibara)
        (NNP:[220..222] K.)))

;section 3 Span:226..313
;Department of Biomedical Research on Food, National Institute of Health,
;Tokyo,  Japan.
(SEC
  (FRAG (NNP:[226..236] Department) (IN:[237..239] of)
        (NNP:[240..250] Biomedical) (NNP:[251..259] Research)
        (NNP:[260..262] on) (NNP:[263..267] Food) (,:[267..268] ,)
        (NNP:[269..277] National) (NNP:[278..287] Institute) (IN:[288..290] of)
        (NNP:[291..297] Health) (,:[297..298] ,) (NNP:[299..304] Tokyo)
        (,:[304..305] ,) (NNP:[307..312] Japan) (.:[312..313] .)))

;sentence 4 Span:317..461
;We have examined the cytotoxicity and cellular incorporation of aflatoxin B1 
;(AFB1) in several types of established and primary cultured cells.
;[381..393]:substance:"aflatoxin B1"
;[396..400]:substance:"AFB1"
(SENT
  (S
    (NP-SBJ (PRP:[317..319] We))
    (VP (VBP:[320..324] have)
      (VP (VBN:[325..333] examined)
        (NP
          (NP (DT:[334..337] the)
            (NML
              (NML (NN:[338..350] cytotoxicity))
              (CC:[351..354] and)
              (NML (JJ:[355..363] cellular) (NN:[364..377] incorporation))))
          (PP (IN:[378..380] of)
            (NP
              (NP (NN:[381..390] aflatoxin) (NN:[391..393] B1))
              (NP (-LRB-:[395..396] -LRB-) (NN:[396..400] AFB1)
                  (-RRB-:[400..401] -RRB-)))))
        (PP-LOC (IN:[402..404] in)
          (NP
            (NP (JJ:[405..412] several) (NNS:[413..418] types))
            (PP (IN:[419..421] of)
              (NP
                (NP (JJ:[422..433] established)
                  (NML-1 (-NONE-:[433..433] *P*)))
                (CC:[434..437] and)
                (NP (JJ:[438..445] primary) (JJ:[446..454] cultured)
                  (NML-1 (NNS:[455..460] cells)))))))))
    (.:[460..461] .)))

;sentence 5 Span:462..599
;The  inhibition of DNA synthesis by AFB1 at 1 microgram/ml was about 0-30% in
;the  established cell lines, including human hepatic cells.
;[481..484]:substance:"DNA"
;[498..502]:substance:"AFB1"
;[506..507]:quantitative-value:"1"
;[508..520]:quantitative-units:"microgram/ml"
;[525..536]:quantitative-value:"about 0-30%"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[462..465] The) (NN:[467..477] inhibition))
      (PP (IN:[478..480] of)
        (NP (NN:[481..484] DNA) (NN:[485..494] synthesis)))
      (PP (IN:[495..497] by)
        (NP (NN:[498..502] AFB1)))
      (PP (IN:[503..505] at)
        (NP
          (NP (CD:[506..507] 1) (NN:[508..517] microgram))
          (PP (SYM:[517..518] /)
            (NP (NN:[518..520] ml))))))
    (VP (VBD:[521..524] was)
      (NP-PRD
        (QP (RB:[525..530] about) (CD:[531..532] 0) (HYPH:[532..533] -)
            (CD:[533..535] 30))
        (NN:[535..536] %))
      (PP-LOC (IN:[537..539] in)
        (NP
          (NP (DT:[540..543] the) (JJ:[545..556] established)
              (NN:[557..561] cell) (NNS:[562..567] lines))
          (,:[567..568] ,)
          (PP (VBG:[569..578] including)
            (NP (JJ:[579..584] human) (JJ:[585..592] hepatic)
                (NNS:[593..598] cells))))))
    (.:[598..599] .)))

;sentence 6 Span:600..779
;In chicken primary  hepatocytes, however, DNA synthesis as well as RNA and
;protein syntheses were  strongly inhibited by much lower concentrations of
;AFB1, e.g., 0.1 microgram/ml.
;[642..645]:substance:"DNA"
;[667..670]:substance:"RNA"
;[675..682]:substance:"protein"
;[750..754]:substance:"AFB1"
;[762..765]:quantitative-value:"0.1"
;[766..778]:quantitative-units:"microgram/ml"
(SENT
  (S
    (PP-LOC (IN:[600..602] In)
      (NP (NN:[603..610] chicken) (JJ:[611..618] primary)
          (NNS:[620..631] hepatocytes)))
    (,:[631..632] ,)
    (ADVP (RB:[633..640] however))
    (,:[640..641] ,)
    (NP-SBJ-2
      (NP (NN:[642..645] DNA) (NN:[646..655] synthesis))
      (CONJP (RB:[656..658] as) (RB:[659..663] well) (IN:[664..666] as))
      (NP
        (NP (NN:[667..670] RNA)
          (NML-1 (-NONE-:[670..670] *P*)))
        (CC:[671..674] and)
        (NP (NN:[675..682] protein)
          (NML-1 (NNS:[683..692] syntheses)))))
    (VP (VBD:[693..697] were)
      (ADVP (RB:[699..707] strongly))
      (VP (VBN:[708..717] inhibited)
        (NP-2 (-NONE-:[717..717] *))
        (PP (IN:[718..720] by)
          (NP-LGS
            (NP
              (NP
                (ADJP (RB:[721..725] much) (JJR:[726..731] lower))
                (NNS:[732..746] concentrations))
              (PP (IN:[747..749] of)
                (NP (NN:[750..754] AFB1))))
            (,:[754..755] ,)
            (NP
              (ADVP (FW:[756..760] e.g.))
              (,:[760..761] ,)
              (NP (CD:[762..765] 0.1) (NN:[766..775] microgram))
              (PP (SYM:[775..776] /)
                (NP (NN:[776..778] ml))))))))
    (.:[778..779] .)))

;sentence 7 Span:781..874
;In contrast, chicken primary fibroblasts showed almost no significant
;response  to the toxin.
;[868..873]:substance:"toxin"
(SENT
  (S
    (PP (IN:[781..783] In)
      (NP (NN:[784..792] contrast)))
    (,:[792..793] ,)
    (NP-SBJ (NN:[794..801] chicken) (JJ:[802..809] primary)
            (NNS:[810..821] fibroblasts))
    (VP (VBD:[822..828] showed)
      (NP
        (NP (RB:[829..835] almost) (DT:[836..838] no)
            (JJ:[839..850] significant) (NN:[851..859] response))
        (PP (TO:[861..863] to)
          (NP (DT:[864..867] the) (NN:[868..873] toxin)))))
    (.:[873..874] .)))

;sentence 8 Span:875..992
;Microsomal cytochrome P-450 activities in hepatic tissues were  10-20-fold
;higher than those in fibroblastic tissues.
;[886..902]:cyp450:"cytochrome P-450"
;[939..949]:quantitative-value:"10-20-fold"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[875..885] Microsomal)
        (NML (NN:[886..896] cytochrome) (NN:[897..902] P-450))
        (NNS:[903..913] activities))
      (PP-LOC (IN:[914..916] in)
        (NP (JJ:[917..924] hepatic) (NNS:[925..932] tissues))))
    (VP (VBD:[933..937] were)
      (ADJP-PRD
        (ADJP
          (ADVP
            (QP (CD:[939..941] 10) (HYPH:[941..942] -) (CD:[942..944] 20))
            (HYPH:[944..945] -) (RB:[945..949] fold))
          (JJR:[950..956] higher))
        (PP (IN:[957..961] than)
          (NP
            (NP (DT:[962..967] those))
            (PP-LOC (IN:[968..970] in)
              (NP (JJ:[971..983] fibroblastic) (NNS:[984..991] tissues)))))))
    (.:[991..992] .)))

;sentence 9 Span:993..1151
;The amount of [3H]AFB1  incorporated into acid-insoluble materials in the
;primary hepatocytes was also  10-100-fold more than that in the primary
;fibroblasts.
;[1007..1015]:substance:"[3H]AFB1"
;[1035..1039]:substance:"acid"
;[1050..1059]:substance:"materials"
;[1097..1108]:quantitative-value:"10-100-fold"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[993..996] The) (NN:[997..1003] amount))
      (PP (IN:[1004..1006] of)
        (NP
          (NP (NN:[1007..1015] -LSB-3H-RSB-AFB1))
          (VP (VBN:[1017..1029] incorporated)
            (NP (-NONE-:[1029..1029] *))
            (PP (IN:[1030..1034] into)
              (NP
                (ADJP (NN:[1035..1039] acid) (HYPH:[1039..1040] -)
                      (JJ:[1040..1049] insoluble))
                (NNS:[1050..1059] materials)))
            (PP-LOC (IN:[1060..1062] in)
              (NP (DT:[1063..1066] the) (JJ:[1067..1074] primary)
                  (NNS:[1075..1086] hepatocytes)))))))
    (VP (VBD:[1087..1090] was)
      (ADVP (RB:[1091..1095] also))
      (ADJP-PRD
        (ADJP
          (ADVP
            (QP (CD:[1097..1099] 10) (HYPH:[1099..1100] -) (CD:[1100..1103] 100))
            (HYPH:[1103..1104] -) (RB:[1104..1108] fold))
          (JJR:[1109..1113] more))
        (PP (IN:[1114..1118] than)
          (NP
            (NP (DT:[1119..1123] that))
            (PP-LOC (IN:[1124..1126] in)
              (NP (DT:[1127..1130] the) (JJ:[1131..1138] primary)
                  (NNS:[1139..1150] fibroblasts)))))))
    (.:[1150..1151] .)))

;sentence 10 Span:1152..1365
;However, a significant  amount of AFB1, which was enough to induce cytotoxic
;effects on the primary  hepatocytes, could be incorporated into the primary
;fibroblasts when the  concentrations of AFB1 were increased.
;[1186..1190]:substance:"AFB1"
;[1345..1349]:substance:"AFB1"
(SENT
  (S
    (ADVP (RB:[1152..1159] However))
    (,:[1159..1160] ,)
    (NP-SBJ-4
      (NP
        (NP (DT:[1161..1162] a) (JJ:[1163..1174] significant)
            (NN:[1176..1182] amount))
        (PP (IN:[1183..1185] of)
          (NP (NN:[1186..1190] AFB1))))
      (,:[1190..1191] ,)
      (SBAR
        (WHNP-3 (WDT:[1192..1197] which))
        (S
          (NP-SBJ-3 (-NONE-:[1197..1197] *T*))
          (VP (VBD:[1198..1201] was)
            (ADJP-PRD (JJ:[1202..1208] enough)
              (S
                (NP-SBJ (-NONE-:[1208..1208] *))
                (VP (TO:[1209..1211] to)
                  (VP (VB:[1212..1218] induce)
                    (NP (JJ:[1219..1228] cytotoxic) (NNS:[1229..1236] effects))
                    (PP-LOC (IN:[1237..1239] on)
                      (NP (DT:[1240..1243] the) (JJ:[1244..1251] primary)
                          (NNS:[1253..1264] hepatocytes)))))))))))
    (,:[1264..1265] ,)
    (VP (MD:[1266..1271] could)
      (VP (VB:[1272..1274] be)
        (VP (VBN:[1275..1287] incorporated)
          (NP-4 (-NONE-:[1287..1287] *))
          (PP (IN:[1288..1292] into)
            (NP (DT:[1293..1296] the) (JJ:[1297..1304] primary)
                (NNS:[1305..1316] fibroblasts)))
          (SBAR-ADV
            (WHADVP-2 (WRB:[1317..1321] when))
            (S
              (NP-SBJ-1
                (NP (DT:[1322..1325] the) (NNS:[1327..1341] concentrations))
                (PP (IN:[1342..1344] of)
                  (NP (NN:[1345..1349] AFB1))))
              (VP (VBD:[1350..1354] were)
                (VP (VBN:[1355..1364] increased)
                  (NP-1 (-NONE-:[1364..1364] *))
                  (ADVP-TMP-2 (-NONE-:[1364..1364] *T*)))))))))
    (.:[1364..1365] .)))

;sentence 11 Span:1366..1619
;Characterization of the AFB1-associated  cellular components showed that most
;of them were DNA, RNA, and proteins in the  primary hepatocytes, while in the
;primary fibroblasts a large portion of the  incorporated AFB1 was recovered
;from lipid fractions.
;[1390..1394]:substance:"AFB1"
;[1457..1460]:substance:"DNA"
;[1462..1465]:substance:"RNA"
;[1471..1479]:substance:"proteins"
;[1579..1583]:substance:"AFB1"
;[1603..1608]:substance:"lipid"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1366..1382] Characterization))
      (PP (IN:[1383..1385] of)
        (NP (DT:[1386..1389] the)
          (ADJP (NN:[1390..1394] AFB1) (HYPH:[1394..1395] -)
                (JJ:[1395..1405] associated))
          (JJ:[1407..1415] cellular) (NNS:[1416..1426] components))))
    (VP (VBD:[1427..1433] showed)
      (SBAR (IN:[1434..1438] that)
        (S
          (NP-SBJ
            (NP (JJS:[1439..1443] most))
            (PP (IN:[1444..1446] of)
              (NP (PRP:[1447..1451] them))))
          (VP (VBD:[1452..1456] were)
            (NP-PRD
              (NP (NN:[1457..1460] DNA) (,:[1460..1461] ,) (NN:[1462..1465] RNA)
                  (,:[1465..1466] ,) (CC:[1467..1470] and)
                  (NNS:[1471..1479] proteins))
              (PP-LOC (IN:[1480..1482] in)
                (NP (DT:[1483..1486] the) (JJ:[1488..1495] primary)
                    (NNS:[1496..1507] hepatocytes))))
            (,:[1507..1508] ,)
            (SBAR-ADV (IN:[1509..1514] while)
              (S
                (PP-LOC (IN:[1515..1517] in)
                  (NP (DT:[1518..1521] the) (JJ:[1522..1529] primary)
                      (NNS:[1530..1541] fibroblasts)))
                (NP-SBJ-1
                  (NP (DT:[1542..1543] a) (JJ:[1544..1549] large)
                      (NN:[1550..1557] portion))
                  (PP (IN:[1558..1560] of)
                    (NP (DT:[1561..1564] the) (JJ:[1566..1578] incorporated)
                        (NN:[1579..1583] AFB1))))
                (VP (VBD:[1584..1587] was)
                  (VP (VBN:[1588..1597] recovered)
                    (NP-1 (-NONE-:[1597..1597] *))
                    (PP (IN:[1598..1602] from)
                      (NP (NN:[1603..1608] lipid) (NNS:[1609..1618] fractions)))))))))))
    (.:[1618..1619] .)))

;sentence 12 Span:1620..1734
;In addition, the selective  binding of [3H]AFB1 to several proteins was
;observed only in the primary  hepatocytes.
;[1659..1667]:substance:"[3H]AFB1"
;[1679..1687]:substance:"proteins"
(SENT
  (S
    (PP (IN:[1620..1622] In)
      (NP (NN:[1623..1631] addition)))
    (,:[1631..1632] ,)
    (NP-SBJ-1
      (NP (DT:[1633..1636] the) (JJ:[1637..1646] selective)
          (NN:[1648..1655] binding))
      (PP (IN:[1656..1658] of)
        (NP (NN:[1659..1667] -LSB-3H-RSB-AFB1)))
      (PP (TO:[1668..1670] to)
        (NP (JJ:[1671..1678] several) (NNS:[1679..1687] proteins))))
    (VP (VBD:[1688..1691] was)
      (VP (VBN:[1692..1700] observed)
        (NP-1 (-NONE-:[1700..1700] *))
        (ADVP (RB:[1701..1705] only))
        (PP-LOC (IN:[1706..1708] in)
          (NP (DT:[1709..1712] the) (JJ:[1713..1720] primary)
              (NNS:[1722..1733] hepatocytes)))))
    (.:[1733..1734] .)))

;sentence 13 Span:1735..1801
;The possible role of the AFB1-binding proteins are also discussed.
;[1760..1764]:substance:"AFB1"
;[1773..1781]:substance:"proteins"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1735..1738] The) (JJ:[1739..1747] possible)
          (NN:[1748..1752] role))
      (PP (IN:[1753..1755] of)
        (NP (DT:[1756..1759] the)
          (ADJP (NN:[1760..1764] AFB1) (HYPH:[1764..1765] -)
                (VBG:[1765..1772] binding))
          (NNS:[1773..1781] proteins))))
    (VP (VBP:[1782..1785] are)
      (ADVP (RB:[1786..1790] also))
      (VP (VBN:[1791..1800] discussed)
        (NP-1 (-NONE-:[1800..1800] *))))
    (.:[1800..1801] .)))

;section 14 Span:1805..1849
;PMID: 1697481 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1805..1809] PMID) (::[1809..1810] :) (CD:[1811..1818] 1697481)
        (NN:[1819..1820] -LSB-) (NNP:[1820..1826] PubMed) (::[1827..1828] -)
        (NN:[1829..1836] indexed) (IN:[1837..1840] for)
        (NNP:[1841..1849] MEDLINE-RSB-)))
